CLEVIPREX® (clevidipine) Dosing and Administration

Описание: This video is a step-by-step walkthrough of the proper administration of CLEVIPREX® (clevidipine), including dosing, titration, and the transitioning of patients off therapy.

Share this video with colleagues interested in managing blood pressure for hypertensive patients working in cardiology, neurology, critical care, emergency medicine, and anesthesiology.
Subscribe for more insights on CLEVIPREX.

CLEVIPREX is not indicated for the prevention or treatment of stroke.

INDICATION
CLEVIPREX® (clevidipine) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable.

IMPORTANT SAFETY INFORMATION
CLEVIPREX® (clevidipine) Injectable Emulsion is contraindicated in patients with:
• Allergies to soybeans, soy products, eggs, or egg products;
• Defective lipid metabolism seen in conditions such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia; and
• Severe aortic stenosis.

CLEVIPREX® is intended for intravenous use. Use aseptic technique and discard any unused product within 12 hours of stopper puncture.

Hypotension and reflex tachycardia are potential consequences of rapid upward titration of CLEVIPREX®. If either occurs, decrease the dose of CLEVIPREX®. There is limited experience with short-duration therapy with beta-blockers as a treatment for CLEVIPREX®-induced tachycardia. Beta-blocker use for this purpose is not recommended.

CLEVIPREX® contains approximately 0.2 g of lipid per mL (2.0 kcal). Lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism.

Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully.

CLEVIPREX® is not a beta-blocker, does not reduce heart rate, and gives no protection against the effects of abrupt beta-blocker withdrawal. Beta-blockers should be withdrawn only after a gradual reduction in dose.

Patients who receive prolonged CLEVIPREX® infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.

There is no information to guide use of CLEVIPREX® in treating hypertension associated with pheochromocytoma.

Most common adverse reactions for CLEVIPREX® (＞2%) are headache, nausea, and vomiting.

Please see link to Full Prescribing Information in the About section.

CLEVIPREX® is a registered trademark of Chiesi Farmaceutici S.p.A.
©2026 Chiesi USA, Inc. All rights reserved
PP-CA-00305 V1.0

#CLEVIPREX #clevidipine #HCP #Chiesi_USA #Dosing #IVTherapy #BloodPressure #Administration #Ad